FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib) September 30, 2025
Ph 1/2a Plixorafenib Data Demonstrated Prolonged Duration of Effect in BRAF Altered Thyroid Cancers September 23, 2025
Plixorafenib demonstrated mPFS of 64 months and a CBR of 85.7% in patients with MAPKi-naïve BRAF V600-mutated papillary thyroid cancer September 16, 2025
AKIR001 cleared to start Ph 1 clinical trial in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, SCCHN, and NSCLC November 5, 2024
FDA grants full approval to selpercatinib for RET fusion-positive medullary thyroid cancer October 1, 2024
Approvals received for BRAFTOVI and MEKTOVI for Expanded Use for Two New Indications in Japan May 21, 2024
Retevmo® (selpercatinib) Demonstrates Superior PFS Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer September 6, 2023
